Frank Tsai

991 citations

36 papers · 483 indexed · h-index 14

Impact in

Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
Immunology
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Immune Cell Function and Interaction

Papers in

Oncology 22
- Cancer Immunotherapy and Biomarkers 11
- CAR-T cell therapy research 4
- HER2/EGFR in Cancer Research 4
- Pancreatic and Hepatic Oncology Research 4
Biological Psychiatry 1

Co-authors: Todd M. Bauer Siqing Fu Michael S. Gordon Aaron R. Hansen Eric J. Sherman Kyriakos P. Papadopoulos Filip Jankú Michael J. Pishvaian
Journals: Journal of Clinical Oncology (16 papers)Cancer Research (4 papers)Annals of Oncology (3 papers)ESMO Open (2 papers)Cancers (1 paper)
Partner nations: United States Canada Australia

In The Last Decade

Frank Tsai

36 papers receiving 473 citations

Peers

Countries citing papers authored by Frank Tsai

Since Specialization

Citations

This map shows the geographic impact of Frank Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Tsai more than expected).

Fields of papers citing papers by Frank Tsai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Tsai. The network helps show where Frank Tsai may publish in the future.

Co-authors

The 25 scholars most cited alongside Frank Tsai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frank Tsai Line = papers co-authored together Frank Tsai links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Immersive Virtual Reality for Enabling Patient Experience and Enrollment in Oncology Clinical Trials: A Feasibility Study Cancers ·Frank Tsai, Laman A. Gray, Amy Mirabella, Margaux Steinbach, Jacqueline M. Garrick, Nadine J. Barrett, Nelson J. Chao, Frédéric Zenhausern	2025	1
2	A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies. Journal of Clinical Oncology ·Frank Tsai, Michael J. Birrer, Jason R. Brown, Sanjay Chandrasekaran, Vincent Chung, Richard C. Frank, Edward G. Garmey, Shirish M. Gadgeel, Thomas J. George, Shadia I. Jalal, Andrew Poklepovic, Jennifer Segar, Alexander I. Spira, Jue Jillian Zhang, Anup Kasi	2024	2
3	A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations ESMO Open ·Jordi Rodón, Estelamari Rodríguez, Michael L. Maitland, Frank Tsai, Mark A. Socinski, Jordan Berlin, Jacob Thomas, Tareq Al Baghdadi, I.‐M. Wang, Cunlan Guo, Mohammad‐Taghi Golmakani, Lorraine N. Clark, Mihaela Gazdoiu, M. Li, A. W. Tolcher	2024	21
4	CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial Investigational New Drugs ·Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller, Aaron R. Hansen, Jong Seok Lee, Frank Tsai, Benjamin Solomon, Tae Min Kim, Christian Rolfo, Vincent L. Giranda, Yixin Ren, Fang Liu, Bhargava Kandala, Tomoko Freshwater, Judy S. Wang	2024	33
5	Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study ESMO Open ·Alain P. Algazi, Kyriakos P. Papadopoulos, Frank Tsai, Aaron R. Hansen, Natasha Angra, Mayukh Das, Siddharth Sheth, Lillian L. Siu	2024	4
6	742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors SHILAP Revista de lepidopterología ·Jong Chul Park, David Berz, Manish Sharma, Erminia Massarelli, Ralph J. Hauke, Frank Tsai, David S. Hong, Neal S. Akhave, Justin Call, Jennifer W. Carlisle, Rachel E. Sanborn, Naomi B. Haas, John Hamm, D. Ross Camidge, Alexander I. Spira, Vasily Andrianov, Brianne O’Neill, Heather Kinkead, Anthony W. Tolcher	2023	2
7	CTNI-76. EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394) IN RECURRENT, PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST) Neuro-Oncology ·Macarena de la Fuente, Nicholas Butowski, Jennie Taylor, Rona Yaeger, Frank Tsai, Filip Jankú, Carl E. Allen, Natraj Reddy Ammakkanavar, Glenn Michelson, Ping Jiang, Michael Paz, Alexia Tussay-Lindenberg, Kongming Wang, Stacie Peacock Shepherd, Irina Kline, Eric J. Sherman, Jordi Rodón	2023	1
8	762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors SHILAP Revista de lepidopterología ·Sharon Wilks, Benedito A. Carneiro, Gregory M. Coté, Jason T. Henry, Shiraj Sen, Alexander I. Spira, Frank Tsai, Judy S. Wang, Marsha Crochiere, Shui He, (unknown), (unknown), Bin Zhang, Anthony W. Tolcher	2023	1
9	PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study. Journal of Clinical Oncology ·Jordi Rodón, Cesar A. Perez, Kit Man Wong, Michael L. Maitland, Frank Tsai, Jordan Berlin, Ken Liao, I‐Ming Wang, Lada Markovtsova, Ira Jacobs, Nora Cavazos, Meng Li, Anthony W. Tolcher	2021	26
10	Phase 1A clinical trial of the first-in-class fascin inhibitor NP-G2-044 evaluating safety and anti-tumor activity in patients with advanced and metastatic solid tumors. Journal of Clinical Oncology ·Vincent Chung, Komal Jhaveri, Daniel D. Von Hoff, Xin‐Yun Huang, Edward G. Garmey, Jillian Zhang, Frank Tsai	2021	16
11	Abstract CT212: Expanded phase 1/2a study of PLX8394, a novel next generation BRAF inhibitor in patients with advanced, unresectable solid tumors with alterations in BRAF Cancer Research ·Filip Jankú, Eric J. Sherman, Rona Yaeger, Aparna Parikh, Ryan J. Sullivan, Lynn G. Feun, Macarena de la Fuente, Frank Tsai, Michael A. Gordon, Carl E. Allen, Marc S. Rudoltz, Kathe Balinski, Steven D. Averbuch, Michael Vidne, Gabi Tarcic	2021	1
12	Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C), and paricalcitol (P)neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology ·Erkut Borazanci, Gayle Jameson, Courtney Snyder, Frank Tsai, Michael S. Gordon, Sunil Sharma, Carol Guarnieri, Amar Thosani, Syed Rahmanuddin, Ronald L. Korn, Steven Sckolnik, Sharon Salontai, Rachel Wyman, Susan Haag, Kevin Gosselin, Daniel D. Von Hoff, Albert Amini	2020	1
13	An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology ·Dana E. Rathkopf, Mansoor N. Saleh, Frank Tsai, Mehmet Asım Bilen, Lee S. Rosen, Marco M. Gottardis, Jeffrey R. Infante, Bonne J. Adams, Lilian Liu, Charles P. Theuer, James L. Freddo, Neeraj Agarwal	2019	4
14	Abstract CT007: Safety and immunogenicity of a personalized neoantigen-Listeria vaccine in cancer patients Cancer Research ·J. Randolph Hecht, Jonathan W. Goldman, Sandy Hayes, David Balli, Michael F. Princiotta, Justin Dennie, John Heyburn, Tammy Sands, Sumitra Sheeri, Robert G. Petit, Andres Gutierrez, Frank Tsai	2019	11
15	A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer Cancer Chemotherapy and Pharmacology ·Amita Patnaik, Michael S. Gordon, Frank Tsai, Kyri Papadopoulous, Drew Rasco, Samashritha Beeram, Siqing Fu, Filip Jankú, Scott M. Hynes, Sushma R. Gundala, Melinda D. Willard, Wei Zhang, Aimee Bence Lin, David S. Hong	2018	45
16	Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC). Journal of Clinical Oncology ·Daniel C. Cho, Amit Mahipal, Afshin Dowlati, Warren Chow, Neil H. Segal, Ki Y. Chung, Bryan J. Schneider, John Nemunaitis, Albiruni Ryan Abdul Razak, Frank Tsai, Ani Sarkis Balmanoukian, Lyudmila Bazhenova, Feng Xiao, Natasha Angra, Shaad E. Abdullah, Jason J. Luke	2018	29
17	Abstract CT112: Durvalumab + tremelimumab in patients with metastatic urothelial cancer Cancer Research ·Arjun Vasant Balar, Amit Mahipal, Enrique Grande, Víctor M. Villalobos, Sébastien Salas, Taek Won Kang, Se Hyun Kim, Thomas Powles, Frank Tsai, Aung Naing, Albiruni Abdul Razak, Yohann Loriot, Ji Youl Lee, Sang Joon Shin, Rafael Morales‐Barrera, Natasha Angra, Feng Xiao, Shaad E. Abdullah, Michiel S. van der Heijden	2018	13
18	Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors. Journal of Clinical Oncology ·Michael A. Postow, James J. Harding, Matthew D. Hellmann, Michael S. Gordon, Frank Tsai, Joseph A. O' Donoghue, Jason S. Lewis, Anna M. Wu, William Le, Ronald L. Korn, Wolfgang Weber, Jedd D. Wolchok, Neeta Pandit‐Taskar	2018	6
19	Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology ·Lillian L. Siu, Kyriakos P. Papadopoulos, Frank Tsai, Aaron R. Hansen, Paul B. Robbins, Xia Li, Dominic W. Lai, John A. Blake-Haskins, Matthew G. Fury	2015	2
20	A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer Cancer ·Matthew G. Fury, Eric J. Sherman, Alan L. Ho, Han Xiao, Frank Tsai, Oby Nwankwo, Camelia S. Sima, Adrian Heguy, Nora Katabi, Sofia Haque, David G. Pfister	2013	35

About Frank Tsai

Frank Tsai is a scholar working on Oncology, Biological Psychiatry, Biotechnology, Cancer Research and Immunology, having authored 36 papers that have together received 483 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (5 papers), CAR-T cell therapy research (4 papers), HER2/EGFR in Cancer Research (4 papers), Radiopharmaceutical Chemistry and Applications (4 papers), Pancreatic and Hepatic Oncology Research (4 papers), Immunotherapy and Immune Responses (4 papers) and Melanoma and MAPK Pathways (3 papers). The work is most often cited by research in Oncology (278 citations), Immunology (154 citations), Biological Psychiatry (17 citations), Cancer Research (58 citations) and Otorhinolaryngology (13 citations). Frank Tsai has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Todd M. Bauer, Siqing Fu, Michael S. Gordon, Aaron R. Hansen, Eric J. Sherman, Kyriakos P. Papadopoulos, Filip Jankú, Michael J. Pishvaian, Keith Orford and Jeffrey R. Infante. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, ESMO Open and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact